Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib Alone or in Combination in Relapsed/Refractory Marginal Zone Lymphoma
2023-509350-63-00Phase 2Authorised
- Sponsor
- Acerta Pharma
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of acalabrutinib in marginal zone B-cell lymphoma (MZL) and mature B-cell lymphoma (2 arms), sponsored by Acerta Pharma. Primary endpoint: Overall response rate (ORR). Planned start Oct 2024; status: authorised.
02
Drugs
acalabrutinib
03
Conditions
marginal zone B-cell lymphoma (MZL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2023-509350-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509350-63-00.